San Francisco expands access to an antibiotic pill that may prevent some bacterial STIs

A preventive antibiotic pill is now widely available in San Francisco after research showed that it can be highly effective at preventing some bacterial sexually transmitted infections, or STIs. The medicine is called Doxy PEP, short for doxycycline post-exposure prophylaxis. It is taken after sex, rather than before it, to reduce the chance of infection.

The treatment has attracted attention because bacterial STIs can cause uncomfortable symptoms and difficult conversations. Tyler Toler, who has experienced chlamydia, gonorrhea, and syphilis, described problems including itching, burning, discharge, and difficulty swallowing. He also worried about telling sexual partners that they might have been exposed to an infection.

After learning about Doxy PEP, Toler began taking it a day or two after sex without a condom. He says he has not had an STI for three years. For him, the treatment has reduced some of the anxiety connected with sexual health and possible exposure.

The wider use of Doxy PEP has also created an important medical question. Antibiotics kill or control bacteria, but some bacteria can survive and become resistant. When this happens, medicines may no longer work as well, making infections more difficult to treat.

Doctors are especially concerned about gonorrhea because it has already developed resistance to this class of antibiotics. They fear that rapid use of Doxy PEP could increase that problem. This does not mean the preventive treatment is being rejected. Instead, its benefits must be considered alongside the long-term need to protect antibiotics so they remain effective.

The debate reflects a broader challenge in modern healthcare: a treatment can offer clear benefits to individuals while also creating risks that must be monitored across the population.